Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 609
- Registration Number
- NCT01697072
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 254
- Registration Number
- NCT01696396
- Locations
- 🇬🇧
Research Site, Torquay, United Kingdom
🇺🇸Hospital, New York, New York, United States
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 58
- Registration Number
- NCT01695876
- Locations
- 🇳🇿
Research Site, Grafton, Auckland, New Zealand
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
- Conditions
- PsoriasisPsoriatic Arthritis
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT01690299
- Locations
- 🇺🇸
University of California Irvine-Department of Dermatology, Irvine, California, United States
🇺🇸Florida Academic Dermatology Center, Miami, Florida, United States
🇺🇸International Dermatology Research, Miami, Florida, United States
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT01688739
- Locations
- 🇧🇪
Research Site, Leuven, Belgium
Safety Study of AMG 557 in Subjects With Lupus Arthritis
- Conditions
- Lupus Arthritis, Systemic Lupus Erythematosus
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT01683695
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 116
- Registration Number
- NCT01677858
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸James R. Berenson M.D. Inc., West Hollywood, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1501
- Registration Number
- NCT01668589
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT01666977
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Osteonecrosis of the Jaw (ONJ) Case Registry
- Conditions
- Osteonecrosis of the Jaw
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 327
- Registration Number
- NCT01666106
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom